CIDRAP newsletters options
As global cases top 220 million, surges continue in Southeast Asia and Oceania.
Results from an observational cohort study of pregnant women indicated a 96% vaccine effectiveness (VE) against COVID-19 infection and an 89% VE against hospitalization for the Pfizer/BioNTech vaccine in pregnant women, according to a study in Nature Medicine today.
A new study by researchers in Pakistan details the impact and response to treatment among children diagnosed as having extensively drug-resistant (XDR) typhoid infections.
The state has stepped into oxygen negotiations, created resource depots, and taken other actions.
Also, Africa is struggling to meet its end-of-September vaccination coverage goal of 10%.
None of the specified outcomes in 6.2 million vaccine recipients met the criteria for a safety signal.
The US surge has driven child COVID-19 hospitalization rates to pandemic highs.
Our weekly wrap-up of antimicrobial stewardship & antimicrobial resistance scans
A survey across 73 countries assessing the impact of COVID-19 on the prevention and control of antimicrobial resistance (AMR) highlights reduced availability of nursing, medical, and public health staff for AMR efforts. The study was published today in the Journal of Antimicrobial Chemotherapy.
COVID-19 vaccine effectiveness (VE) against the Delta (B1617.2) variant was 65% in those fully vaccinated, according to a population-based study in Norway. The results, published in Eurosurveillance yesterday, looked at 4,204,859 infected adults without previous COVID-19 from mid-April to mid-August.
"A transparent, thorough, and objective review of the data by the FDA is critical."
The ECDC says a third dose should already be considered in the immune-compromised.
After years of decline, US hospitals saw significant increases in HAIs.
The odds of long COVID-19 fall by more than half after two doses of vaccine.
The rheumatoid arthritis drug baricitinib was shown to reduce mortality in hospitalized COVID-19 patients, according to a randomized, controlled trial published in The Lancet Respiratory Medicine yesterday. Baricitinib acts as a Janus kinases inhibitor and is under emergency use authorization to treat severe COVID-19 by the US Food and Drug Administration.
Even those who had mild COVID-19 are at increased risk for major declines in kidney function.
August was the fourth-worst month of the pandemic for new COVID-19 cases.
Also, global health experts call on world leaders to hold a UN summit on ending the pandemic.
Admission screening for carbapenem-resistant Enterobacterales (CRE) at a Vietnamese children's hospital was associated with reduced CRE acquisition, hospital-acquired infections (HAIs), duration of hospital stay, and costs, according to a study published this week in Antimicrobial Resistance and Infection Control.
Pre-hospital antiplatelet therapy, most commonly aspirin, was associated with significantly lower in-hospital mortality rates for COVID-19 patients, according to a study this week in the Journal of Thrombosis and Haemostasis.
